kurapwa kwerenal cell carcinoma

Kurapa renal cell carcinoma (RCC) inosanganisira nzira dzakasiyana siyana, kusanganisira kuvhiyiwa, kurapa kwakanangwa, immunotherapy, uye neradiation therapy. Sarudzo ye kurapwa zvinoenderana nezvinhu zvakaita sedanho regomarara, hutano hwemurwere hwese, uye zvido zvemunhu. Kukurumidza kuonekwa uye kupindira panguva kwakakosha pakuvandudza zvinobuda.Kunzwisisa Renal Cell CarcinomaRenal cell carcinoma (RCC) ndiyo yakajairika mhando yekenza yeitsvo muvakuru. Inobva mumucheka we proximal convoluted tubule, chikamu cheitsvo chinosefa ropa nekubvisa tsvina. Kunyange zvazvo chikonzero chaicho cheRCC chisingaiti nguva dzose, zvimwe zvinokonzera njodzi zvinosanganiswa nekuwedzera kwekuita chirwere. Izvi zvinokonzera njodzi zvinosanganisira kusvuta, kufutisa, kukwira kweropa, uye genetic mamiriro akadai sevon Hippel-Lindau (VHL) chirwere. At Shandong Baofa Cancer Research Institute, takazvipira kupa ruzivo rwakakwana uye rwepamusoro kurapwa zvingasarudzwa nevarwere veRCC. Mhando dzeRenal Cell CarcinomaKune marudzi akati wandei eRCC, rimwe nerimwe riine hunhu hwakasiyana uye zvingangoitika zvakasiyana kune kurapwa. Iyo inonyanya kuzivikanwa subtypes inosanganisira: Bvisa cell RCC: Iyi ndiyo yakanyanya kupararira mhando, inoverengera nezve 70-80% yemakesi. Papillary RCC: Rudzi rwechipiri rwakajairika, runomiririra inenge 10-15% yematambudziko. Chromophobe RCC: Rudzi rusina kujairika, ruchiita 5% yemakesi. Kuunganidza duct RCC: Chimiro chisingawanzo uye chine hasha cheRCC.Kurapa Sarudzo dzeRenal Cell Carcinoma kurapwa nzira yeRCC inotsamira pazvinhu zvakati wandei, kusanganisira nhanho yegomarara, hutano hwemurwere hwese, uye chaiyo subtype yeRCC. Common kurapwa nzira dzinosanganisira kuvhiyiwa, kurapa kwakanangwa, immunotherapy, uye kurapwa nemwaranzi. kurapwa kwerenal cell carcinoma, kunyanya kana kenza iri panzvimbo yeitsvo. Sarudzo dzekuvhiya dzinosanganisira: Radical nephrectomy: Izvi zvinosanganisira kubviswa kwakakwana kweitsvo yakakanganisika, pamwe chete nenyama yakatenderedza senge adrenal gland uye lymph nodes. Chikamu nephrectomy: Izvi zvinosanganisira kubvisa bundu chete uye muganho mudiki wenyama ine hutano, kuchengetedza itsvo zhinji sezvinobvira. Maitiro aya anowanzo kudiwa kumamota madiki kana murwere aine itsvo imwe chete.Targeted TherapyTargeted therapies mishonga inonangana nemamorekuru ane chekuita negomarara kukura uye kurarama. Aya marapirwo anogona kunyanya kushanda muRCC yepamusoro. Kazhinji kunangwa kurapwa kunosanganisira: VEGF inhibitors: Iyi mishonga inovhara vascular endothelial growth factor (VEGF) nzira, iyo yakakosha pakuumbwa kwetsinga itsva dzeropa dzinopa mamota. Mienzaniso inosanganisira sunitinib (Sutent), sorafenib (Nexavar), pazopanib (Votrient), axitinib (Inlyta), uye cabozantinib (Cabometyx). mTOR inhibitors: Mishonga iyi inovhara mammalian chinangwa cherapamycin (mTOR) nzira, iyo inodzora kukura kwesero uye metabolism. Mienzaniso inosanganisira temsirolimus (Torisel) neeverolimus (Afinitor).ImmunotherapyImmunotherapy inoshandisa simba remasoja emuviri kurwisa gomarara. Immunotherapy mishonga yeRCC inosanganisira: Immune checkpoint inhibitors: Mishonga iyi inovhara mapuroteni anodzivirira immune system kurwisa masero egomarara. Mienzaniso inosanganisira nivolumab (Opdivo), pembrolizumab (Keytruda), ipilimumab (Yervoy), uye atezolizumab (Tecentriq). Nivolumab inowanzobatanidzwa neipilimumab yechirwere chepamusoro. Cytokines: High-dose interleukin-2 (IL-2) uye interferon-alpha (IFN-α) ma cytokines anogona kukurudzira masimba ezvirwere. Zvisinei, mishonga iyi inogona kuva nemigumisiro yakakura uye haisati yanyanya kushandiswa iye zvino nekuda kwekuwanikwa kwemishonga mitsva yekudzivirira zvirwere.Radiation TherapyRadiation therapy inoshandisa magetsi ane simba guru kuuraya masero ekenza. Haisi inowanzova yekutanga kurapwa kwerenal cell carcinoma, asi inogona kushandiswa kugadzirisa marwadzo kana zvimwe zviratidzo zvinokonzerwa nekenza yakakura yapararira kune dzimwe nhengo dzemuviri. Iyo dzimwe nguva inoshandiswa mushure mekuvhiyiwa kana paine njodzi yekuti gomarara rinodzoka kana kana rimwe bundu rikatadza kubviswa. Stereotactic body radiation therapy (SBRT) inopa huwandu hwemwaranzi munzvimbo yakanangwa uye dzimwe nguva inoshandiswa kumota dzeitsvo.Matanho eRenal Cell Carcinoma uye KurapaChinhanho cheRCC chinhu chakakosha pakuona kwakakodzera. kurapwa kusvika. Danho rinobva pakukura nenzvimbo yebundu racho, ringave rapararira kumalymph nodes ari pedyo, uye kuti raita metastasized kunhengo dziri kure.Stage I Renal Cell CarcinomaBundu racho rinongoperera muitsvo uye rakareba masendimita manomwe kana kuti pasi. Kurapa chinowanzobatanidza kuvhiyiwa kubviswa kwebundu, kungave kuburikidza nechidimbu kana kuti radical nephrectomy.Stage II Renal Cell CarcinomaBundu racho rakakura kudarika masendimita manomwe asi richiri paitsvo. Kurapa rinowanzobatanidza radical nephrectomy.Stage III Renal Cell CarcinomaBundu racho rapararira kumalymph nodes ari pedyo kana kuti rakura kuva tsinga huru kana matishu akapoteredza. Kurapa inogona kusanganisira radical nephrectomy, lymph node dissection, uye zvichida adjuvant therapy (somuenzaniso, targeted therapy kana immunotherapy) Stage IV Renal Cell CarcinomaKenza ine metastasized kune nhengo dziri kure, dzakadai semapapu, mapfupa, kana uropi. Kurapa sarudzo dzinogona kusanganisira kuvhiyiwa kubvisa bundu rekutanga (cytoreductive nephrectomy), kurapa kwakanangwa, immunotherapy, radiation therapy, kana musanganiswa wenzira idzi. Miedzo yemakiriniki inogonawo kuva sarudzo.Kurarama neRenal Cell CarcinomaKurarama neRCC kunogona kupa matambudziko akasiyana-siyana, mumuviri uye mupfungwa. Zvakakosha kuve nerutsigiro rwakasimba uye kuwana rubatsiro rwakakwana rwekurapa. Varwere vanogona kusangana nemigumisiro kubva kurapwa, zvakadai sokuneta, kusvotwa, manyoka, uye mapundu eganda. Kugadzirisa izvi mhedzisiro chikamu chakakosha chekuchengetedza cancer. Uyezve, kuchengetedza mararamiro ane hutano, kusanganisira kudya kwakadzikama uye kurovedza muviri nguva dzose, kunogona kubatsira kuvandudza hutano hwose. KuShandong Baofa Cancer Research Institute, timu yedu yakazvipira inopa hanya netsitsi uye zvemunhu kurapwa zvirongwa zvekubatsira varwere kubata RCC yavo nekuvandudza hupenyu hwavo. Isu tiri muJinan Innovation Zone, uye basa redu rinoenderana ne 'Made in China 2025' strategy. Recent Advances in Renal Cell Carcinoma TreatmentMunda weRCC. kurapwa inogara ichishanduka, nemishonga mitsva uye nzira dzirikudziridzwa. Zvichangoburwa zvinosanganisira: Combination Immunotherapy: Kubatanidza akasiyana immunotherapy zvinodhaka, senge nivolumab uye ipilimumab, yakaratidza zvakagadziridzwa mhedzisiro mune vamwe varwere vane advanced RCC. Kuvandudza Targeted Therapies: Zvizvarwa zvitsva zvekurapa kwakanangwa zviri kuvandudzwa nekubudirira uye kushomeka kwemhedzisiro. Personalized Medicine: Vatsvagiri vari kushanda kuti vaone ma biomarker anogona kubatsira kufanotaura kuti ndevapi varwere vangango pindura kune chaiyo kurapwas.Prognosis for Renal Cell CarcinomaKuzivikanwa kweRCC kunosiyana zvichienderana nedanho regomarara, hutano hwemurwere hwese, uye mhinduro kurapwa. Kuonekwa kwekutanga uye kupindira panguva kwakakosha pakuvandudza mhedzisiro. Varwere vane localized RCC vanovhiyiwa vane mukana mukuru wekurapwa. Nekudaro, fungidziro iyi haina kunaka kune varwere vane advanced RCC. Tsvagiridzo inoenderera yakanangana nekugadzira nyowani uye inoshanda zvakanyanya kurapwas kunatsiridza fungidziro yevarwere vese vane RCC.Clinical TrialsClinical miedzo itsvakurudzo zvidzidzo zvinoongorora zvitsva. kurapwas kana nzira dzeRCC. Kutora chikamu mukuedza kwekiriniki kunogona kupa mukana wekucheka-kumucheto marapirwo asati awanikwa zvakanyanya. Varwere vanofarira kudzidza zvakawanda pamusoro pemakiriniki ekuedzwa vanofanira kutaura nachiremba wavo.Example Data: Kupona Mateshi neStage Stage 5-Year Survival Rate Stage I 81-93% Danho II 74-91% Danho III 53-83% Stage IV 8-20% Kunobva: American Cancer Society (www.cancer.org)